Key Highlights

● Candel Therapeutics plunged on Friday.

● Candel pushed back the timing of its planned approval filing.

● The filing covers a prostate-cancer treatment.

● Wednesday's Fed minutes could offer fresh rate-hike clues.

Candel Therapeutics (NASDAQ:CADL) plunged on Friday, November 13, 2026, ranking among the sharpest decliners trending on the Nasdaq Composite. The trigger was a change in timing: the company pushed its planned approval filing for its prostate-cancer treatment to mid-2027.

Candel is a clinical-stage biotechnology company developing immunotherapies for cancer. For companies at this stage, the regulatory filing is one of the most important milestones on the calendar. It is the step that can open the door to a potential approval and, eventually, commercial revenue. When that milestone moves further out, investors often recalculate the value of the program right away.

Why timing matters so much for biotech

Small and mid-sized biotech stocks are valued largely on expectations about future products rather than current sales. Each step toward approval, from trial readouts to regulatory submissions, tends to shape the stock price. A delay can matter in several ways.

First, it pushes back the point at which a treatment could begin generating revenue, which reduces the present value of those future sales in investors' models. Second, a longer runway before a potential launch can raise questions about how much cash a company will need along the way. Third, delays can create uncertainty, and uncertainty is something the market typically discounts quickly in development-stage companies.

The move on Friday reflects investors absorbing a later timeline for a key program.

A difficult tape for risk assets

The broader market made it harder for any stock with negative news to find buyers. The Nasdaq Composite closed at 25,136.27, down 229.82 points, while the S&P 500 fell 30.73 points to 7,561.67. The Russell 2000, a common home for smaller biotech names, slipped 8.57 points to 2,790.49. Only the Dow Jones Industrial Average gained, rising 50.46 points to 52,347.55.

Much of the day's selling was concentrated in chip and AI-hardware stocks after Nvidia (NASDAQ:NVDA) said on Thursday that chief executive Jensen Huang had resigned, without giving a reason. But rate worries hung over everything. October producer prices showed the hottest annual pace since November 2022, even though the monthly gain was a touch cooler than expected, and the 10-year Treasury Yield climbed to its highest since October.

Fed officials kept up their hawkish tone. Boston Fed President Susan Collins said, "I would think some additional policy tightening is warranted soon," according to market data. Traders see a December rate hike as near-certain. Higher rates tend to weigh on long-duration Assets such as development-stage biotech, where most of the expected value sits years in the future.

Sentiment was also cautious overall. The Fear & Greed index stood at 39, in "fear" territory, while the VIX Volatility gauge rose 0.60 to 19.30 after briefly topping 20 in the morning.

Reading the reaction

Biotech investors often distinguish between delays tied to scientific setbacks and those tied to process or planning. Without more detail from the company, it is difficult to say which category this falls into, and the market's sharp reaction reflects that uncertainty as much as the new date itself.

What to watch next for Candel Therapeutics

Investors will look for any additional disclosure from Candel about what is driving the revised filing schedule and whether other milestones have shifted. Updates on cash runway and trial progress will be key to how the market reassesses the company.

On the macro side, FOMC minutes are due on Wednesday, November 18, and the Fed meets on December 8 and 9. With traders expecting a hike, rate-sensitive sectors like small-cap biotech may stay volatile.